Capital Group Private Client Services Inc. Cuts Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN

Capital Group Private Client Services Inc. lowered its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 87.3% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,907 shares of the biopharmaceutical company’s stock after selling 19,965 shares during the period. Capital Group Private Client Services Inc.’s holdings in Regeneron Pharmaceuticals were worth $1,635,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently added to or reduced their stakes in the company. CoreCap Advisors LLC raised its stake in shares of Regeneron Pharmaceuticals by 9.2% during the 3rd quarter. CoreCap Advisors LLC now owns 238 shares of the biopharmaceutical company’s stock worth $134,000 after buying an additional 20 shares in the last quarter. Strait & Sound Wealth Management LLC lifted its holdings in shares of Regeneron Pharmaceuticals by 3.5% in the 3rd quarter. Strait & Sound Wealth Management LLC now owns 628 shares of the biopharmaceutical company’s stock valued at $353,000 after buying an additional 21 shares during the period. Parkside Financial Bank & Trust boosted its stake in shares of Regeneron Pharmaceuticals by 14.8% in the third quarter. Parkside Financial Bank & Trust now owns 163 shares of the biopharmaceutical company’s stock valued at $92,000 after buying an additional 21 shares in the last quarter. MAI Capital Management grew its holdings in Regeneron Pharmaceuticals by 2.1% during the third quarter. MAI Capital Management now owns 1,028 shares of the biopharmaceutical company’s stock worth $578,000 after acquiring an additional 21 shares during the period. Finally, Independence Bank of Kentucky grew its holdings in Regeneron Pharmaceuticals by 7.7% during the third quarter. Independence Bank of Kentucky now owns 308 shares of the biopharmaceutical company’s stock worth $173,000 after acquiring an additional 22 shares during the period. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Insider Activity

In related news, Director Huda Y. Zoghbi sold 1,638 shares of the firm’s stock in a transaction that occurred on Thursday, February 19th. The shares were sold at an average price of $781.33, for a total transaction of $1,279,818.54. Following the sale, the director owned 1,703 shares in the company, valued at approximately $1,330,604.99. This trade represents a 49.03% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Bonnie L. Bassler sold 1,500 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Wednesday, January 7th. The stock was sold at an average price of $800.00, for a total transaction of $1,200,000.00. Following the completion of the sale, the director directly owned 1,703 shares of the company’s stock, valued at $1,362,400. The trade was a 46.83% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 5,274 shares of company stock worth $4,142,738. Corporate insiders own 7.02% of the company’s stock.

Regeneron Pharmaceuticals Stock Down 1.2%

Shares of NASDAQ:REGN opened at $772.03 on Wednesday. The company has a quick ratio of 3.39, a current ratio of 4.13 and a debt-to-equity ratio of 0.09. The company has a market capitalization of $81.62 billion, a P/E ratio of 18.58, a P/E/G ratio of 2.10 and a beta of 0.41. Regeneron Pharmaceuticals, Inc. has a 52-week low of $476.49 and a 52-week high of $821.11. The stock’s fifty day simple moving average is $770.79 and its 200-day simple moving average is $692.02.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Friday, January 30th. The biopharmaceutical company reported $11.44 EPS for the quarter, topping analysts’ consensus estimates of $10.74 by $0.70. The firm had revenue of $3.88 billion during the quarter, compared to analysts’ expectations of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 13.04% and a net margin of 31.41%.The firm’s quarterly revenue was up 2.5% compared to the same quarter last year. During the same quarter last year, the business posted $12.07 EPS. As a group, equities research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Thursday, March 5th. Stockholders of record on Friday, February 20th were issued a dividend of $0.94 per share. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.5%. This is a boost from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. The ex-dividend date was Friday, February 20th. Regeneron Pharmaceuticals’s payout ratio is presently 9.05%.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on REGN shares. Zacks Research downgraded Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Friday, February 6th. Royal Bank Of Canada upped their price target on shares of Regeneron Pharmaceuticals from $745.00 to $765.00 and gave the stock a “sector perform” rating in a research note on Monday, March 2nd. Cantor Fitzgerald increased their price target on shares of Regeneron Pharmaceuticals from $740.00 to $800.00 and gave the company an “overweight” rating in a report on Monday, February 2nd. Guggenheim raised their price objective on shares of Regeneron Pharmaceuticals from $865.00 to $975.00 and gave the company a “buy” rating in a research note on Monday, February 9th. Finally, Wells Fargo & Company boosted their price objective on shares of Regeneron Pharmaceuticals from $745.00 to $800.00 and gave the stock an “equal weight” rating in a report on Monday, February 2nd. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and nine have assigned a Hold rating to the company. According to data from MarketBeat.com, Regeneron Pharmaceuticals currently has an average rating of “Moderate Buy” and an average target price of $802.27.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.